The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma

Annals of Surgery

Volumn 240, Issue 4, 2004, Pages 686-697

  Eilber, Fritz C ^a   Eilber, Frederick R ^b   Eckardt, Jeffery ^b   Rosen, Gerald ^b   Riedel, Elyn ^a   Maki, Robert G ^a   Brennan, Murray F ^a   Singer, Samuel ^a   Pollock, Raphael E ^c   Eilber, Frederick C ^c   Wanebo, Harold J ^c   Goodnight Jr , James E ^c   Meakins, Jonathan L ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Surgery ^*

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; MESNA; METHOTREXATE;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIMB AMPUTATION; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; EXTREMITIES; FEMALE; HUMANS; IFOSFAMIDE; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; SOFT TISSUE NEOPLASMS; SURVIVAL RATE;

EID: 4644341568     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000141710.74073.0d     Document Type: Conference Paper

References (31)

1. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg. 1996;33:817-872.
2. Eilber FC, Eilber FR. Soft tissue sarcoma. In: Cameron ed. Current Surgical Therapy. Seventh Edition. St. Louis, MS, Mosby 2001;1213-1218.
3. Linehan DC, Lewis JJ, Leung D, et al. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol. 2000;18:1637-1643.
4. Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg. 1994;219:165-173.
5. Pisters PWT, Leung DHY, Woodruff J, et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679-1689.
6. Lewis JJ, Leung D, Casper ES, et al. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg. 1999;134:190-194.
7. Eilber FC, Rosen G, Nelson S, et al. High grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003;237:218-226.
8. Koea JB, Leung D, Lewis JJ, et al. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Ann Surg Oncol. 2003;10:432-440.
9. Fletcher CM, Akerman P, Cin I, et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) collaborative study group. Am J Pathol. 1996;148:623-630.
10. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7:3977-3987.
11. Gebhard S, Coindre JM, Michels JJ, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002;26:601-616.
12. Chang HR, Hajdu SI, Collin C, et al. The prognostic value of histologic subtypes in primary extremity liposarcoma. Cancer. 1989;64:1514-1520.
13. Chang HR, Gaynor J, Tan C, et al. Multifactorial analysis of survival in primary extremity liposarcoma. World J Surg. 1990;14:610-618.
14. Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358-370.
15. Henricks WH, Chu YC, Goldblum JR, et al. Dedifferentiated liposarcoma: a clinicopathologic analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am J Surg Path. 1997;21:271-281.
16. McCormick D, Mentzel T, Beham A, et al. Dedifferentiated liposarcoma: clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol. 1994;18:1213-1223.
17. Dei Tos, AP, Liposarcoma: new entities and evolving concepts. Ann Diagn Pathol. 2000;4:252-266.
18. Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350:1647-1654.
19. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7:126-131.
20. Antman KH. Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol. 1992;19:13-20.
21. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276-1285.
22. Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 2000;4:151-160.
23. Gortzak E, Azzarelli A, Buesa J, et al. A randomized phase II study on neo-adjuvant chemotherapy for "high-risk" adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096-1103.
24. Frustaci S, Gherlinzoni F, DePaoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcoma of the extremity and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-1247.
25. Fletcher C, Unni K, Mertens F, et al. Pathology and genetics of tumors of soft tissue and bone. In: Kleihues P, Sobin L, eds. World Health Organization Classification of Tumors, Vol, 4. Lyon, France: International Agency for Research on Cancer Press; 2002:427
26. Verweij J, Seynaeve C, The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin Radiat Oncol. 1999;9:352-359.
27. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;65:80-84.
28. Eilber FC, Rosen G, Eckardt J, et al. Treatment induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203-3209.
29. Antonescu CR, Elahi A, Healy JH, et al. Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements. Clin Cancer Res. 2000;6:2788-2793.
30. Demitri GD, Fletcher CDM, Mueller, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci. 1999;96:3951-3956.
31. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligand for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci. 1997;94:237-241.